Benefits of global mutant huntingtin lowering diminish over time in a Huntington’s disease mouse model

We have developed an inducible Huntington’s disease (HD) mouse model that allows temporal control of whole-body allele-specific mutant huntingtin (mHtt) expression. We asked whether moderate global lowering of mHtt (~50%) was sufficient for long-term amelioration of HD-related deficits and, if so, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchionini, Deanna M., Liu, Jeh-Ping, Ambesi-Impiombato, Alberto, Kerker, Kimberly, Cirillo, Kim, Bansal, Mukesh, Mushlin, Rich, Brunner, Daniela, Ramboz, Sylvie, Kwan, Mei, Kuhlbrodt, Kirsten, Tillack, Karsten, Peters, Finn, Rauhala, Leena, Obenauer, John, Greene, Jonathan R., Hartl, Christopher, Khetarpal, Vinod, Lager, Brenda, Rosinski, Jim, Aaronson, Jeff, Alam, Morshed, Signer, Ethan, Muñoz-Sanjuán, Ignacio, Howland, David, Zeitlin, Scott O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714791/
https://www.ncbi.nlm.nih.gov/pubmed/36278490
http://dx.doi.org/10.1172/jci.insight.161769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714791/
https://www.ncbi.nlm.nih.gov/pubmed/36278490
http://dx.doi.org/10.1172/jci.insight.161769

Ejemplares similares